This case report describes the use of nebulized hydromorphone for management of dyspnea in advanced cancer in home hospice care. The patient was intolerant of morphine; nebulized hydromorphone was used as an alternative to nebulized morphine for dyspnea and found to be both safe and effective.
Ripamonti C, Fulfaro F, Bruera E: Dyspnea in patients with advanced cancer: incidence, causes and treatments. Cancer Treat Rev. 1998; 24: 69-80.
2.
LeGrand SB, Walsh D: Palliative management of dyspnea in advanced cancer. Curr Opin Oncol. 1999; 11: 250-254.
3.
Nelson K, Walsh D: Management of dyspnea in advanced cancer. Cancer Bull. 1991; 4: 423-426.
4.
Farncombe M, Chater S: Clinical application of nebulized opioids for treatment of dyspnea in patients with malignant disease. Support Care Cancer. 1994; 2: 184-187.
5.
Walsh D: Dyspnea in advanced cancer. Lancet. 1993; 342: 450-451.
6.
Farncombe M, Chater S: Case studies outlining use of nebulized morphine for patients with end-stage chronic lung and cardiac disease. J Pain Symptom Manage. 1993; 8: 221-225.
7.
Dudgeon D, Rosenthal S: Management of dyspnea and cough in patients with cancer. Hematol Oncol Cli North Am. 1996; 10: 157-171.
8.
Quelch PC, Faulkner DE, Yun JW: Nebulized opioids in the treatment of dyspnea. J Palliative Care. 1997; 13(3): 48-52.
9.
Farncombe M, Chater S, Gillin A: The use of nebulized opioids for breathlessness: a chart review. Palliat Med. 1994; 8: 306-312.
10.
Bruera E, MacEachern T, Ripamonti C, Hanson J: Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med. 1993; 119: 906-907.
11.
Cohen MH, Johnston Anderson A, Krasnow SH, et al.: Continuous intravenous infusion of morphine for severe dyspnea. Southern Med J. 1991; 84: 229-234.
12.
Boyd K, Kelly M: Oral morphine as symptomatic treatment of dyspnea in patients with advanced cancer. Palliat Med. 1997; 11: 277-281.
13.
Woodcock AA, Gross ER, Gellert A, Shah S, Johnson M, Geddes D: Effects of dihydrocodeine, alcohol and caffeine on obstructive lung disease and normal blood gases. N Engl J Med. 1981; 305: 1611-1616.
14.
Conno F de, Spoldi E, Caraceni A, Ventafridda V: Does pharmacological treatment affect the sensation of breathlessness in terminal cancer patients?Palliat Med. 1991; 5: 237-243.
15.
Cowcher K, Hanks G: Long-term management of respiratory symptoms in advanced cancer. J Pain Symptom Manage. 1990; 5: 320-330.
16.
Roger DF, Barnes PG: Opioids inhibition of neurally medicated mucous secretion in human bronchi. Lancet. 1989; I: 930-931.
17.
Barnes P: Neuropeptides in the lung: Localization, function, and pathophysiologic implications. J. Aller Clini Immuno. 1987; 79(2): 285-295.
18.
Davis CL, Penn K, A’Hern R, et al.: Single-dose randomized controlled trial of nebulized morphine in patients with cancer-related breathlessness. Palliat Med. 1996; 10:64-65.
19.
Masood AR, Reed JW, Thomas SHL: Lack of effect of inhaled morphine on exercise-induced breathlessness in chronic obstructive pulmonary disease. Thorax. 1995; 50: 629-634.
20.
Noseda A, Carpiaux JP, Markstein C, et al.: Disabling dyspnea in patients with advanced disease: lack of effect of nebulized morphine. Eur Respir J. 1997; 10: 1079-1083.
21.
Lawlor P, Turner K, Hanson J, Bruera E: Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain. 1997; 72: 79-85.
22.
Kennedy SK, Longnecker DE: History and principles of anesthesiology. In Gilman AG, Rall TW, Nies AS, Taylor P (eds): The pharmacological basis of therapeutics. New York: Pergamon, 1990, 295-301.
23.
Seaman L: Symptom management algorithms. A handbook for palliative care. Yakima, WA: Intellicard, 1999, 50-51.
